Novel Augmentation of DAOIB and Antioxidant for Early Dementia

This study is testing a combination of two supplements — DAOIB (a compound that supports brain receptor function) and an antioxidant — to slow cognitive decline in people with early-stage Alzheimer's disease or mild cognitive impairment. **You may be eligible if...** - You have been diagnosed with Alzheimer's disease or mild cognitive impairment - Your cognitive test score (MMSE) is between 10 and 26 - Your clinical dementia rating (CDR) is 0.5 (mild) or 1 (moderate) **You may NOT be eligible if...** - Your vascular risk score (Hachinski score) is above 4, suggesting vascular dementia - You have Parkinson's disease, epilepsy, or dementia with psychotic features - You have a major depressive disorder or serious physical illness - You have severe vision or hearing impairment Talk to your doctor to see if this trial is right for you.